Complementary proteomic and transcriptomic analyses have identified Claudin-4 as one of the most upregulated proteins in cisplatin-resistant ovarian cancer cells, linking its overexpression to impaired DNA-damage response, epithelial–mesenchymal transition signatures, and restored cisplatin sensitivity upon silencing [24,33,34]. The gene discussed is CLDN4; the disease is ovarian carcinoma.